1,520 Alzheimers Headlines
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute
St. Joseph's Hospital and Medical Center
"2 NEW THERAPIES FOR ALZHEIMER'S"
Produced by MD Health Channel
Executive Editor.....Anne-Merete Robbs
CEO..............Stan Swartz

Dr. Reyes and his team are constantly working on new medicines and new solutions...You will receive news alerts...information on new trials as Dr Reyes announces them!
"2 NEW THERAPIES FOR ALZHEIMER'S"
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

St. Joseph's Hospital and Medical Center



DO YOU HAVE ALZHEIMERS?
 
"HELP DR. REYES... IN HIS BATTLE TO FIND A CURE...
.HE NEEDS YOUR HELP:
YOU CAN HELP WIN THE BATTLE FOR A CURE BY JOINING A TRIAL!!"....

Stan Swartz, CEO,
The MD Health Channel



"You'll receive all medication and study based procedures at
no charge

if you qualify for one of the many trials being conducted at Barrow Neurological Institute."
 

"Dr. Reyes Changed My Life"

- John Swartz
92 Years Old
Attorney at Law
"Dr.Reyes Changed My Life "
1:18
"At 92...I had lost my will to live"
5:48
Tips on Aging
2:29
"Dr. Reyes gave me customized health care"
2:09

Patricio Reyes M.D.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute

St. Joseph's Hospital and Medical Center
"PRESERVING BRAIN FUNCTIONS "
Runtime: 50:22
Runtime: 50:22
"2 NEW THERAPIES FOR ALZHEIMER'S"
Runtime: 10:27
Runtime: 10:27
ALZHEIMER'S AWARENESS PROGRAMS
Runtime: 5:00
Runtime: 5:00
BIOMEDICAL RESEARCH IN ALZHEIMER'S DISEASE
PDF Document 850 kb

Download Free

4 TALES OF NEUROSURGERY &
A PIANO CONCERT BY DR. SPETZLER...
Plus 2 books written by Survivors for Survivors!
Robert F. Spetzler M.D.
Director, Barrow Neurological Institute

J.N. Harber Chairman of Neurological Surgery

Professor Section of Neurosurgery
University of Arizona
TALES OF NEUROSURGERY:
A pregnant mother..a baby..faith of a husband.. .plus... Cardiac Standstill: cooling the patient to 15 degrees Centigrade!
Lou Grubb Anurism
The young Heros - kids who are confronted with significant medical problems!
2 Patients...confronted with enormous decisions before their surgery...wrote these books to help others!
A 1 MINUTE PIANO CONCERT BY DR. SPETZLER

Michele M. Grigaitis MS, NP
Alzheimer's Disease and Cognitive Disorders Clinic

Barrow Neurological Clinics
COPING WITH DEMENTIA
 
Free Windows Media Player Click

Links
Barrow Neurological Institute

Archives
October 2006  
November 2006  
December 2006  
January 2007  
February 2007  
March 2007  
May 2007  
June 2007  
November 2007  
December 2007  
April 2008  
July 2008  
August 2008  
September 2008  
October 2008  
November 2008  
December 2008  
January 2009  
February 2009  
March 2009  
April 2009  
May 2009  
February 2010  
March 2013  
May 2013  
November 2013  
January 2014  
February 2014  
March 2014  
April 2014  
May 2014  
June 2014  
July 2014  
June 2016  
July 2016  
August 2016  
September 2016  
October 2016  
November 2016  
December 2016  
January 2017  
February 2017  
March 2017  
April 2017  
May 2017  
June 2017  
July 2017  
August 2017  
September 2017  
October 2017  
November 2017  
December 2017  
January 2018  
February 2018  
March 2018  
April 2018  
May 2018  
June 2018  
July 2018  
August 2018  
September 2018  
October 2018  
November 2018  
December 2018  
January 2019  
February 2019  
March 2019  
April 2019  
May 2019  
June 2019  
July 2019  
August 2019  
September 2019  
October 2019  
November 2019  
December 2019  
January 2020  
February 2020  
March 2020  
April 2020  
May 2020  
June 2020  
July 2020  
August 2020  
September 2020  
October 2020  
November 2020  
December 2020  
January 2021  
February 2021  
March 2021  
April 2021  
May 2021  
June 2021  
July 2021  
August 2021  
September 2021  
October 2021  
November 2021  
December 2021  
January 2022  
February 2022  
March 2022  
April 2022  
May 2022  
June 2022  
July 2022  
August 2022  
September 2022  
October 2022  
November 2022  
December 2022  
January 2023  
February 2023  
March 2023  
April 2023  
May 2023  
June 2023  
July 2023  
August 2023  
September 2023  
October 2023  
November 2023  
December 2023  
January 2024  
February 2024  
March 2024  

This page is powered by Blogger. Isn't yours?

Friday, April 7, 2017

 

FDA approves sale of genetic tests for risk of Alzheimer’s and other diseases






























Consumers will soon be able to mail a saliva sample to genetic testing company and get back data on their risk for developing diseases such as Parkinson’s, late-onset Alzheimer’s, and celiac disease.

The Food and Drug Administration on Thursday granted approval to genetic testing company 23andMe to offer such direct-to-consumer tests for 10 conditions.

But Dr. Jeffrey Shuren, director of FDA’s Center for Devices and Radiological Health, urged customers not to take their test results as a sure sign that they will — or will not — develop a particular disease.

It’s “important that people understand that genetic risk is just one piece of the bigger puzzle,” Shuren said in a statement.

The FDA’s approval does not extend to diagnostic tests, such as genetic analysis that help determine a woman’s risk for breast cancer and that could lead to treatment decisions such as surgical removal of healthy breasts.

Still, the move was controversial because it will allow consumers to receive weighty information about their genetic risk for dreaded diseases without any counseling from a medical professional. The FDA cautioned that results should not be used to inform treatment decisions and noted that there is always a risk of false positives or false negatives.

The idea of telling consumers by mail that they have an elevated risk of Alzheimer’s — based on a genetic variant in a gene known as APOE — concerned some physicians and researchers. Rudolph Tanzi, a neurology professor at Harvard Medical School, said consumers will “for sure” need genetic counseling along with the test results.

The relationship between Alzheimer’s disease and the APOE variant “is complex and not fully understood,” said Dr. Mary Ganguli, a professor of geriatric psychiatry at the University of Pittsburgh.  For one thing, she said, the association is weaker in African-Americans than in whites. For another, the risk fades with age; if you make it beyond age 80 without developing Alzheimer’s, you’re no longer at elevated risk, even if you have the variant, she said.

“How is someone who orders the test at home and gets this result going to know all this?” Ganguli asked. “Do most of their doctors know?”

23andMe, like several other companies, has been providing customers with reports on their genetic ancestry and some general health information, like whether they’re lactose intolerant or prone to weight gain. The FDA’s move on Thursday greatly widens the market for the company.

Just as significant: The FDA indicated that it will ease the way for 23andMe to sell additional disease risk tests, without extensive regulatory review. Other companies that use a similar process for genetic analysis may also be able to expedite their their path to market.

It’s a significant reversal of fortunes for the Bay Area startup: In 2013, the FDA banned the company from sharing data about disease risk with its customers. Regulators worried that consumers would misinterpret the results from the inexpensive at-home saliva test kit, and allowed 23andMe to only provide ancestry information.

After extensive talks with the FDA, 23andMe was allowed to start sharing some health information with its users in 2015 — offering users carrier screening, for instance, that indicated whether they could pass heritable diseases like cystic fibrosis and Tay-Sachs disease to their children.

The decision to allow 23andMe to disclose disease risk information to consumers has been nearly a year in the making: The company first submitted its request for approval in June 2016, according to Kathy Hibbs, 23andMe’s chief regulatory officer.

“This is an important moment for people who want to know their genetic health risks and be more proactive about their health,”  Anne Wojcicki, 23andMe CEO and cofounder, said in a statement. She also noted that it’s a “significant step forward” for her company.

The Personalized Medicine Coalition, which counts biotech and diagnostic companies and patient groups among its members, also welcomed the FDA’s move. The disease risk tests may “help inform patients’ behaviors and medical decisions,” said Edward Abrahams, the group’s president.

Story Source: The above story is based on materials provided by STATNEWS
Note: Materials may be edited for content and length
Click here to read more